The impact of subjective well-being under neuroleptic treatment on compliance and remission.
The patients' perspective of antipsychotic treatment was largely neglected for a long period. It has only been during the last 10 years, with the development of atypical antipsychotics, that scientific interest in this issue has markedly increased. Numerous studies have shown that the majority of schizophrenic patients are able to fill out a self-rating scale in a meaningful way, and several self-report scales with sufficient internal consistency and good construct validity have been developed. The effects of antipsychotic treatment on psychopathology and on subjective well-being (SW) are not strongly related; the perspectives of the patient and his/her psychiatrist markedly differ. Recent research indicates that SW/quality of life, much more improved by atypical than by typical antipsychotics, has a strong impact on compliance, as well as on the chance of achieving remission. The data strongly suggest that a systematic evaluation of the patient's perspective of antipsychotic treatment is meaningful and necessary to increase compliance, functional outcome, and long-term prognosis.
de Millas
Walter
W
Centre for Psychosocial Medicine, Department for Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Lambert
Martin
M
Naber
Dieter
D
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D006801:Humans; D010349:Patient Compliance / Q000523:psychology*; D017060:Patient Satisfaction; D011569:Psychiatric Status Rating Scales; D011599:Psychopathology; D011788:Quality of Life; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012647:Self-Assessment; D018434:Sickness Impact Profile; D016896:Treatment Outcome
D014150:Antipsychotic Agents